معرفی
Lars Andreas Akslen is a Professor at the Department of Clinical Medicine, University of Bergen, and serves as the Centre Director of CCBIO (Centre for Cancer Biomarkers). He is based at Haukeland University Hospital and leads a major translational cancer research group focused on biomarker discovery and validation.
- Position: Professor, Centre Director of CCBIO
- Institution: University of Bergen
- Department: Department of Clinical Medicine
- Location: Haukeland University Hospital, Bergen, Norway
- Email: lars.akslen@uib.no
His research is centered on translational oncology, with a strong emphasis on identifying and validating novel biomarkers for improved biological classification and grading of malignant tumors. His work spans breast cancer, malignant melanoma, prostate cancer, and gynecologic cancers. By integrating human tumor sample analysis with experimental cell and animal models, his team aims to enhance the clinical utility of biomarkers in predicting aggressive tumor behavior and guiding personalized treatment strategies.
The recent publications highlight a consistent focus on tumor microenvironment, immune biomarkers, imaging mass cytometry, AI in diagnosis, and age-related phenotypes in cancer. There is a strong trend towards high-dimensional spatial profiling and integration of molecular and clinical data to refine prognostic and predictive models.
Lars Andreas Akslen has no listed scientific awards in the provided text.
He leads the Tumor Biology Research Group (established in 1995) and the CCBIO center, indicating significant mentorship and leadership in cancer research. While specific students are not listed, his extensive collaboration network suggests active supervision of PhD and postdoctoral researchers. No specific grants are mentioned, but leadership of a national research center implies substantial funding acquisition.
He is affiliated with CCBIO and the Tumor Biology Research Group, both based at the Department of Clinical Medicine, University of Bergen, and operating from Haukeland University Hospital. These teams focus on translational cancer biomarker research using advanced molecular and imaging technologies.
